HCM - Hutchison China MediTech / Chi-Med

-

$undefined

N/A

(N/A)

Hutchison China MediTech / Chi-Med NASDAQ:HCM HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.

Location: Cheung Kong Center, 48th Floor 2 Queens Road, HK | Website: https://www.hutch-med.com/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.86B

Cash

803.5M

Avg Qtr Burn

-11.74M

Short % of Float

0.10%

Insider Ownership

0.13%

Institutional Own.

4.29%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Renal cell carcinoma, Cancer, Gastric cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) + TAGRISSO Details Non-small cell lung carcinoma, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-306 Details Hematologic malignancies, Blood cancer, Acute myeloid leukemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Primary immune thrombocytopenia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SULANDA (Surufatinib) Details Solid tumor/s, Neuroendocrine tumor, Pancreatic cancer, Cholangiocarcinoma, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + paclitaxel Details Cancer, Solid tumor/s, Gastroesophageal adenocarcinomas, Gastric cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SULANDA (Surufatinib) + Camrelizumab Details Solid tumor/s, Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + Sintilimab Details Renal cell carcinoma, Cancer, Solid tumor/s, Kidney cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tazemetostat Details Follicular lymphoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Amdizalisib (HMPL-689) (PI3K) Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-453 (FGFR 1/2/3) Details Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Cancer, Endometrial cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Non-Hodgkin lymphoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-506 Details Cancer, Leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.